Clinical Trials Logo
  1. Home
  2. Advanced NSCLC
  3. NCT04043195

Nivolumab and Ipilimumab in Combination With Immunogenic Chemotherapy for Patients With Advanced NSCLC — NSCLC  

Advanced NSCLC Clinical Trial

Official title:
Nivolumab (Anti-PD1 Antibody) and Ipilimumab (Anti-CTLA4 Antibody) in Combination With Immunogenic Chemotherapy for Patients With Advanced Non-Small Cell Lung Cancer

Clinical Trial Summary

The purpose of this study is to examine the safety and efficacy of combining Nivolumab and low-dose Oxaliplatin with or without Ipilumumab in patients who have had their advanced NSCLC cancer worsen on or after being treated with certain immunotherapies (drugs that target the immune system). Nivolumab (Opdivo®) is approved by the Food and Drug Administration (FDA) for the treatment of metastatic (the cancer has spread) NSCLC. It is a type of drug called a monoclonal antibody (a type of protein). Monoclonal antibodies bind to other proteins, such as PD-1 (programmed cell death-1), on immune cells, which allows the immune cells to continue working against the tumor. Ipilumumab (Yervoy®) is also a monoclonal antibody, but binds to a protein called CTLA-4 (cytotoxic T-lymphocyte-associated protein 4). Oxaliplatin is a type of immunogenic chemotherapy, which may increase the body's immune response to the cancer. Both are approved for treatment of other types of cancers, but not in patients with NSCLC.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04043195
Study type Interventional
Source University of California, San Diego
Contact
Status Active, not recruiting
Phase Phase 1/Phase 2
Start date August 14, 2019
Completion date December 2025
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT02133196 - T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer Phase 2
Recruiting NCT00813332 - Second-line Therapy Study of Combined Chemotherapy and Endostar to Patients With Non-Small Cell Lung Cancer(NSCLC) Phase 4
Completed NCT03215810 - Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT04982224 - Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Phase 1/Phase 2
Recruiting NCT05609578 - Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation Phase 2
Not yet recruiting NCT04992858 - Ningetinib in Advanced NSCLC Skipping Mutations With MET Exon 14 Skipping Mutations Phase 2
Active, not recruiting NCT03127449 - AST2818 in Advanced Non-Small Cell Lung Cancer With EGFR Mutations N/A
Not yet recruiting NCT06356675 - A Single-arm Pilot Study of Tislelizumab Combined With Anlotinib in Patients With Advanced NSCLC With Driver-negative After Progression to Immunotherapy Phase 4
Completed NCT03074175 - Plasma miRNAs Predict Radiosensitivity of Different Fractionation Regimes in Palliative Radiotherapy for Advanced Non-small Cell Lung Cancer：Multicenter Controlled Study.(RadmiR-01) N/A
Terminated NCT05106335 - A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC Phase 3
Not yet recruiting NCT04229121 - Clinical Sensitivity Verification Study of Circulating Tumor Cells Gene Mutation Detection From Advanced NSCLC Patients
Completed NCT05219162 - Real-World Study on Gene Profile in Patients With Advanced NSCLC Who Progressed on First-Line Osimertinib Therapy(GPS). Phase 4
Not yet recruiting NCT05859217 - A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1) Phase 2
Recruiting NCT03062800 - Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) Phase 2
Completed NCT02055508 - POSITIVE - Study (Part III) Heidelberg N/A